AR-Signaling in Human Malignancies: Prostate Cancer and Beyond
AbstractIn the 1940s Charles Huggins reported remarkable palliative benefits following surgical castration in men with advanced prostate cancer, and since then the androgen receptor (AR) has remained the main therapeutic target in this disease. Over the past couple of decades, our understanding of AR-signaling biology has dramatically improved, and it has become apparent that the AR can modulate a number of other well-described oncogenic signaling pathways. Not surprisingly, mounting preclinical and epidemiologic data now supports a role for AR-signaling in promoting the growth and progression of several cancers other than prostate, and early phase clinical trials have documented preliminary signs of efficacy when AR-signaling inhibitors are used in several of these malignancies. In this article, we provide an overview of the evidence supporting the use of AR-directed therapies in prostate as well as other cancers, with an emphasis on the rationale for targeting AR-signaling across tumor types. View Full-Text
A printed edition of this Special Issue is available here.
Share & Cite This Article
Schweizer, M.T.; Yu, E.Y. AR-Signaling in Human Malignancies: Prostate Cancer and Beyond. Cancers 2017, 9, 7.
Schweizer MT, Yu EY. AR-Signaling in Human Malignancies: Prostate Cancer and Beyond. Cancers. 2017; 9(1):7.Chicago/Turabian Style
Schweizer, Michael T.; Yu, Evan Y. 2017. "AR-Signaling in Human Malignancies: Prostate Cancer and Beyond." Cancers 9, no. 1: 7.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.